Compare LCTX & ULBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | ULBI |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.4M | 102.1M |
| IPO Year | 1996 | 1995 |
| Metric | LCTX | ULBI |
|---|---|---|
| Price | $0.95 | $6.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 35.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 13.00 |
| Revenue | $14,556,000.00 | ★ $191,159,000.00 |
| Revenue This Year | $109.40 | $20.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.45 |
| Revenue Growth | ★ 53.24 | 16.24 |
| 52 Week Low | $0.96 | $4.90 |
| 52 Week High | $2.09 | $8.25 |
| Indicator | LCTX | ULBI |
|---|---|---|
| Relative Strength Index (RSI) | 36.60 | 48.25 |
| Support Level | N/A | $5.59 |
| Resistance Level | $1.18 | $6.33 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 6.30 | 48.24 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company also designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.